
-
iTeos Therapeutics NasdaqGM:ITOS iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Location: 321 Arsenal Street, Watertown, MA, 02472, United States | Website: https://www.iteostherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-131.4M
Cash
520.4M
Avg Qtr Burn
-24.89M
Short % of Float
12.35%
Insider Ownership
1.14%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belrestotug (EOS-448) + Dostarlimab (doublet) Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Belrestotug (EOS-448) + Dostarlimab (doublet) + Nelistotug (triplet) Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
Inupadenant (EOS-850) Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
EOS-215 Details Cancer, Solid tumor/s | Failed Discontinued | |
EOS-984 + Pembrolizumab Details Solid tumor/s, Cancer | Failed Discontinued |